Comparison of the Results of Using β-Interferon-1a Formulations 30 μg for Intramuscular Administration and β-Interferon-1a 44 μg for Subcutaneous Injections in Daily Clinical Practice for the Treatment of Multiple Sclerosis

Objective. To compare results of the treatment of multiple sclerosis (MS) with Genfaxon, CinnoVex, and Rebif. Materials and methods. These agents were used to treat patients living in the Moscow West Administrative District (80 patients) from September 2014 to October 2015. Among these, 30 patients received Genfaxon, 20 received CinnoVex, and 30 received Rebif. Results and conclusions. CinnoVex was withdrawn from 25% of patients receiving it because of clinical inefficacy, with identical exacerbation frequencies before and after treatment. Treatment with Genfaxon for one year produced a significant reduction in exacerbation frequency. The main problem encountered with Genfaxon was a high frequency of side effects. This caused some patients to terminate treatment. Patients receiving Rebif showed a significant reduction in exacerbation frequency, though adverse events also occurred during the first year of treatment. The characteristics of the actions of bioanalogs seen here were generally consistent with previous observations. This identifies the need for an increase in the quality of β-interferon-1a bioanalogs used for the treatment of MS.

from Physiology via xlomafota13 on Inoreader http://ift.tt/2rf9BJ7
via IFTTT